옥트레오타이드 아세트산염

용도

• Adjunctive treatment of chylothorax
• Medical treatment of insulinoma (particularly in patients refractory to or unable to tolerate other medical or surgical therapy)
• Medical treatment of insulinoma (beta cell tumor) particularly in patients refractory to or unable to tolerate other medical or surgical therapy
• Medical treatment of insulinoma
• Adjunctive treatment of gastrinoma
• Adjunctive treatment of chylothorax

투여 방법

가능한 부작용

• Gastrointestinal upset
• Decreased dietary fat absorption
• Biliary sludging or gallstones (with prolonged use)
• Injection site pain

주의사항 및 금기

• Known hypersensitivity to octreotide
• > **Caution**: Use with care in patients with biliary tract disorders or severe renal dysfunction (dosage adjustment may be necessary). Prolonged use (>4 weeks) may increase the risk of gallstone formation. Safety in pregnant or nursing animals is not fully established (FDA Category B in humans).

약물 상호작용

• Beta-blockers: May cause additive bradycardic effects
• Bromocriptine: May increase oral bioavailability
• Calcium-channel blockers: May cause additive bradycardic effects
• Cyclosporine: May reduce cyclosporine levels
• Diuretics: May enhance fluid/electrolyte imbalances
• Food: May reduce fat absorption
• Insulin, oral hypoglycemics: Octreotide can inhibit insulin
• Quinidine: May reduce the quinidine clearance

자주 묻는 질문